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Objectives: To determine, in a multi-ethnic/racial, prospective SLE inception cohort, 
the frequency, attribution, clinical and autoantibody associations with lupus 
psychosis and the short and long-term outcome as assessed by physicians and 
patients. 
Methods: Patients were evaluated annually for 19 neuropsychiatric (NP) events 
including psychosis. SLE disease activity 2000, SLICC/ACR damage index and SF-
36 scores were collected.  Time to event and linear regressions were used as 
appropriate. 
Results: Of 1,826 SLE patients, 88.8% were female, 48.8% Caucasian. The 
meanSD age was 35.1±13.3 years, disease duration 5.64.2 months and follow-up 
7.44.5 years. There were 31 psychotic events in 28/1,826 (1.53%) patients and 
most [(26/28; 93%)] had a single event. In the majority of patients [20/25; (80%)] and 
events [28/31; (90%)] psychosis was attributed to SLE, usually within 3 years of SLE 
diagnosis. Positive associations [hazard ratio and 95% confidence interval [HR 
(95%CI)] with lupus psychosis were prior SLE NP events [3.59, (1.16, 11.14), male 
sex [3.0, (1.20, 7.50)], younger age at SLE diagnosis [(per 10 years younger), 1.45 
(1.01, 2.07)] and African ancestry [4.59 (1.79, 11.76)]. By physician assessment 
most psychotic events resolved by the second annual visit following onset, in parallel 
with an improvement in patient reported SF-36 summary and subscale scores. 
Conclusion: Psychosis is an infrequent manifestation of NPSLE. Generally, it 
occurs early after SLE onset and has a significant negative impact on health status. 
As determined by patient and physician report, the short and long term outlook is 
good for most patients, though careful follow-up is required. 
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Neuropsychiatric (NP) events are one of the features of systemic lupus 
erythematosus (SLE) but their frequency and attribution to SLE or other causes is 
variable. Overall, approximately one third are caused directly by SLE (1), but for 
individual manifestations this varies between 0% and 100% (2, 3). The outcome for 
individual NPSLE manifestations, especially rare NP events, is derived from 
observational cohorts of well characterized patients followed over prolonged periods.  
 
One of the rarer NP events is lupus psychosis which is part of both the ACR (4) and 
SLICC (5) classification criteria for SLE. Characterized by delusions and 
hallucinations, it is a dramatic presentation of NPSLE (6, 7). It is one of the few 
manifestations of nervous system disease in SLE associated, albeit inconsistently, 
with a lupus specific autoantibody against ribosomal P (8-10). The infrequent 
occurrence of psychosis has limited the number of clinical studies and most consist 
of case series obtained by review of medical records.   
 
In the present study of lupus psychosis, we determined its frequency, attribution, 
clinical and autoantibody associations and the outcome assessed by physicians and 
patients in a large, multi-ethnic/racial, prospective, inception cohort of SLE patients. 
Patients and Methods 
Research study network: The study was conducted by the Systemic Lupus 
International Collaborating Clinics (SLICC) (11), a network of 53 investigators in 43 
academic medical centers in 16 countries. The current study involved 31 centers in 
10 countries. Data were collected per protocol at enrollment and annually, submitted 
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to the coordinating center in Halifax, Nova Scotia, Canada and entered into an 
Access database. Appropriate procedures ensured data quality, management and 
security. The Nova Scotia Health Authority central zone Research Ethics Board, 
Halifax, and each of the participating centers’ institutional research ethics review 
boards approved the study. 
 
Patients: Patients fulfilled the ACR classification criteria for SLE (4) which served as 
the date of diagnosis, and provided written informed consent. Enrollment was 
permitted up to 15 months following the diagnosis. Demographic variables, 
education and medication history were collected. Lupus-related variables included 
the SLE Disease Activity Index 2000 (SLEDAI-2K) (12) and SLICC/ACR damage 
index (SDI) (13). Laboratory testing required to determine SLEDAI-2K and SDI 
scores was done at each center.   
 
Neuropsychiatric (NP) events: An enrollment window extended from 6 months 
prior to the diagnosis of SLE up to the actual enrollment date. NP events were 
characterized within this window using the ACR case definitions for 19 NP 
syndromes (14). The clinical diagnosis was supported by investigations, if warranted, 
as per the guidelines. Patients were reviewed annually with a 6-month window 
around the assessment date. New NP events and the status of previous NP events 
since the last study visit were determined at each assessment.   
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The ACR case definition for psychosis (14) is: (i) delusions or hallucinations without 
insight; (ii) causing clinical distress or impairment in social, occupational or other 
relevant areas of functioning; (iii) disturbance should not occur exclusively during 
delirium; (iv) not better accounted for by another mental disorder. Recurring 
episodes of psychosis and other NP events within the enrollment window or within a 
follow-up assessment period were recorded once for that period of observation. The 
date of the first episode was taken as the onset of the event. Once a NP event had 
resolved, a subsequent event of the same type was recorded as a new event. 
 
Attribution of NP events: As with other publications on the SLICC NPSLE inception 
cohort, similar decision rules were used to determine the attribution of NP events 
(15, 16). Factors considered included: (i) temporal onset of NP event(s) in relation to 
the diagnosis of SLE; (ii) concurrent non-SLE factor(s), such as potential causes 
(“exclusions”) or contributing factors (“associations”) for each NP syndrome in the 
glossary for the ACR case definitions of NP events (14). For psychosis the pre-
specified potential alternative causes (“exclusions”) were (a) primary psychotic 
disorder unrelated to SLE (e.g. schizophrenia);  (b) substance or drug induced 
psychotic disorder; (c) psychologically mediated reaction to SLE (brief reactive 
psychosis with major stressor), and the pre-specified potential contributing factors 
(“associations”) were (a) marked psychosocial stress and (b) corticosteroids; (iii) 
finally “common” NP events in normal population controls as described by Ainiala et 
al (17) were identified and included isolated headaches, anxiety, mild depression 
(mood disorders failing to meet criteria for “major depressive-like episodes”), mild 
cognitive impairment (deficits in less than 3 of the 8 specified cognitive domains) and 
polyneuropathy without electrophysiological confirmation. Using these three factors, 
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two attribution decision rules of different stringency (models A and B) were used (15, 
16).  
Attribution model A (most stringent):  NP events which had their onset within the 
enrollment window and had no “exclusions” or “associations” and were not one of the 
NP events identified by Ainiala (17) were attributed to SLE.  
Attribution model B (least stringent): NP events which had their onset within 10 
years of the diagnosis of SLE and were still present within the enrollment window 
and had no “exclusions” and were not one of the NP events identified by Ainiala (17) 
were attributed to SLE. 
By definition, all NP events attributed to SLE using model A were similarly attributed 
using model B. Events which did not fulfill these criteria were classified as non-SLE 
NP events.  
 
Outcome of Psychosis: For every NP event, a physician generated 7-point Likert 
scale was completed at each follow-up assessment until resolution of the event or 
patient demise (1=patient demise, 2=much worse, 3=worse, 4=no change, 
5=improved, 6=much improved, 7=resolved) (18). A patient generated SF-36 
questionnaire was also completed at each assessment and provided subscale, 
mental (MCS) and physical (PCS) component summary scores (18, 19), that were 
unavailable to physicians at their assessments. 
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Autoantibodies: Plasma lupus anticoagulant (LAC), serum IgG anti-cardiolipin, anti-
β2 glycoprotein-I, anti-ribosomal P (anti-P) and anti-NR2 glutamate receptor 
antibodies were measured at the Oklahoma Medical Research Foundation, USA as 
described (20-23).  
 
Statistical analysis: Since there were only 15 patients with psychosis attributed to 
SLE by model A, we used attribution model B and Cox regression to analyze time to 
first SLE psychosis. This included onset of NP events prior to SLE diagnosis in order 
to capture all NP events potentially related to the risk of psychosis. Hazard ratios 
(HR) and 95% confidence intervals (CI) were calculated. Covariates examined 
included sex, race/ethnicity, SLICC sites, post-secondary education, number of ACR 
criteria at enrollment (excluding neurologic disorder), SDI (without NP variables), 
other concurrent NP events and, as continuous variables, age at SLE diagnosis, 
disease duration (in years) and SLEDAI-2K (without NP variables). Binary variables 
indicating autoantibodies present at baseline and follow-up assessments were 
defined when available. Time-varying variables, other than those related to 
autoantibodies, were updated at each assessment. When examining the time-
varying version of the autoantibody variables, autoantibody data in the period before 
enrolment were imputed by their values at enrollment, while autoantibody data at 
follow-up assessments were imputed by the `last observation carried forward’ 
method.  Kaplan-Meier estimates of the survivor function for the time until resolution 
of psychosis were calculated.  For analyses of longitudinal SF-36 subscale and 
summary scores, linear regression with GEE estimation allowed for correlation of 
observations within patients and adjustment variables include time/visit, sex, age at 
SLE diagnosis, race/ethnicity/location, education, SLEDAI-2K and SDI scores 
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(without NP variables), corticosteroids, antimalarials and immunosuppressant use 
since last assessment. 
 
Results 
Patients: 1,826 patients were recruited between October 1999 and December 2011, 
from centers in the United States [n=539 (29.5%)], Europe [n=477 (26.1%)], Canada 
[n=418 (22.9%)], Mexico [n=223 (12.2%)] and Asia [n=169 (9.3%)] (Table 1). The 
number of patient assessments varied from 1 to 19 with a mean follow-up of 7.4±4.5 
years and final assessment follow-up was in March 2017. 
 
Neuropsychiatric (NP) manifestations: NP events (≥1) occurred in 951/1,826 
(52.1%) patients and 488/1826 (26.7%) had ≥ 2 events over the study period. There 
were 1902 unique NP events, encompassing all 19 NP syndromes in the ACR case 
definitions (14). The proportion of NP events attributed to SLE varied from 17.8% 
(attribution model A) to 31.1% (attribution model B) and occurred in 13.3% (model A) 
to 21.1% (model B) of patients. Of the 1902 unique NP events, 1742 (91.6%) 
involved the central nervous system and 160 (8.4%) the peripheral nervous system 
(14). The classification of events into diffuse and focal was 1471 (77.3%) and 431 
(22.7%) respectively (16). 
 
Psychosis: Among 28/1,826 (1.53%) patients with psychosis, 26/28 (93%) had a 
single psychotic event, while one patient each had 2 and 3 discrete events. The 
majority of patients had psychosis attributed to SLE [15/28 (54%) using attribution 
model A and 25/28 (89%) using model B]. Patients with lupus psychosis (model B) 
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were located in centers from Europe (9 patients), Canada (6 patients), USA (5 
patients), Mexico (4 patients) and Asia (1 patient). There was no significant 
association between location and risk of SLE psychosis (p=0.53 in Cox regression) 
taking the number of patients and the duration of follow-up at each site into account. 
The majority of patients with lupus psychosis [20/25 (80%)] had their first episode 
either in the year prior to or within 3 years following the diagnosis of SLE (Figure 1). 
There were 31 psychotic events of which 16/31 (52%) and 28/31 (90%) were 
attributed to SLE using attribution model A and B respectively. The earliest psychotic 
episode occurred 2 months prior to the diagnosis of SLE. 
 
Clinical and laboratory associations with lupus psychosis: Using Cox 
regression we looked for associations with the risk of the first episode of psychosis 
attributed to SLE using attribution model B. Univariate analysis revealed a positive 
association [HR (95%CI)] between male sex [2.58 (1.04,6.41)], younger age at 
diagnosis (per 10 years, 1.36, (1.0,1.88)], African ancestry [4.80 (1.86,12.40)], in 
particular for patients outside the United States [5.53 (1.86,16.42)], concurrent other 
central [3.86 (1.27,11.70)] or diffuse [6.36 (2.12,19.12)] NP events (mood disorder, 
acute confusional state) attributed to SLE, and presence of anti-ribosomal P 
antibodies at the enrollment visit into the cohort [3.31 (1.19,9.21)] and over time 
[3.13 (1.15,8.56)].  
 
Important variables identified in univariate analyses were included in multivariate 
analyses, excluding antibody variables due to reduced sample size consequent to 
missing data (Table 2). The significant positive associations [HR (95%CI)] with lupus 
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psychosis were similar, namely prior SLE NP events [3.59, (1.16,11.14), male sex 
[3.0, (1.20,7.50)], younger age at SLE diagnosis [per 10 years, 1.45, (1.01,2.07)] and 
African ancestry [4.59 (1.79,11.76)]. Further, after adjusting for the demographic 
predictors in Table 2 (sex, age at SLE diagnosis and race/ethnicity), anti-ribosomal P 
antibodies at enrolment [2.29 (0.81,6.46), p=0.11] and over time [2.17 (0.79,5.97), 
p=0.13] were no longer significantly associated with the risk of lupus psychosis  
 
Treatment of SLE psychosis: The treatment of individual patients was at the 
discretion of their attending rheumatologist and was predicated on the overall needs 
of the patient and not only the psychotic event. The following therapies were used 
during the time of the first psychotic events: corticosteroids 23/28 (82.1%) with a 
mean (SD) dose of prednisone of 21.9 (14.9) mg/day, immunosuppressants 
(cyclophosphamide, azathioprine, methotrexate, mycophenolate mofetil) 17/28 
(60.7%), biologics 1/28 (3.6%), antipsychotic drugs 19/28 (67.9%), antidepressants 
11/28 (39.3%), either/both antipsychotic drugs and antidepressants 22/28 (78.6%). 
In 13/28 (46.4%) events corticosteroids had been started prior to the onset of 
psychosis with a mean (SD) dose of 20.3 (13.6). 
 
Clinical outcome and health related quality of life (HRQoL) in patients with 
lupus psychosis: A summary of physician assessments of outcome of lupus 
psychosis is illustrated in Figure 2. Over 80% of the psychotic events had resolved 
by the second annual assessment following onset of the event (Figure 2a). Likewise, 
the maximum and minimum Likert scores over the duration of follow-up illustrates 
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that the majority of psychotic events either improved or resolved over the period of 
observation (Figure 2b). 
 
The mean (SD) SF-36 PCS and MCS scores are shown in Figure 3a for the following 
four patient groups. Group 1 (n=29): visits in patients with onset of lupus psychosis 
since last assessment or with an ongoing psychotic event; Group 2 (n=3379): visits 
in patients with onset of other NP events since last assessment or ongoing other NP 
event(s), including non-SLE psychosis; Group 3 (n=2180): visits in patients with no 
NP events since last assessment and no ongoing NP event(s) but with a history of 
previous NP event(s); Group 4 (n=5893): visits in patients who never had NP 
event(s). The lowest summary scores were in groups 1 and 2 (global p < 0.001 in the 
multivariate analyses) and the negative impact on HRQoL affected all 8 subscales of 
the SF-36 as show in the accompanying spidergram (Figure 3b). 
 
To determine if there was a persistent change in HRQoL following physician 
determined resolution of lupus psychosis, patient generated SF-36 scores were 
compared in the following two groups. Psychosis group (n=29): visits in patients with 
onset of lupus psychosis since last assessment up to its resolution. Resolved group 
(n=112): visits in patients with resolution of lupus psychosis up to their last follow-up 
or recurrence of psychosis. If the psychotic event had both onset and resolution in 
the same interval prior to assessment, SF-36 scores at that assessment were 
included only in the psychosis group. As illustrated in Figure 4a, there was 
substantial improvement in both MCS scores (mean difference: 7.01) and PCS 
scores (mean difference: 4.34) and in all subscales of the SF-36 (Figure 4b) 
concurrent with resolution of lupus psychosis 
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Discussion 
In a large, international, inception cohort study of SLE patients we have 
prospectively documented the frequency, associations and outcomes of psychotic 
events over a mean follow-up of 7.4 years. Our findings confirm and expand upon 
the results of previous cross-sectional and historical studies of psychosis in SLE (6-
8, 24, 25). The majority of psychotic events were directly attributed to SLE, had a 
predilection to occur early in the course of the disease and were more frequent in 
male patients. Psychosis was also more frequent in those patients of African 
ancestry as is also the case for non-SLE patients with the same race/ethnicity (26). 
The outcome of lupus psychosis, as determined by both physicians and patients, 
was positive and emphasizes the importance of diagnosing and treating this rare 
manifestation of NPSLE. 
 
Studies of NPSLE conducted prior to the introduction in 1999 of the ACR case 
definitions for NPSLE did not have a uniform definition for psychosis. Using the ACR 
case definition, the frequency of psychosis has been reported to vary between 0% 
and 17.1% (6, 17, 27-30) and in our study it was 1.53% (28/1826). Using a well-
defined process for determining attribution, we confirmed that the majority of 
psychotic events were due to SLE. In keeping with other NPSLE events and with 
other severe SLE manifestations such as nephritis (31), there was a predilection for 
psychosis to occur early in the disease course, usually within the first 3 years 
following the diagnosis of SLE. Univariate analysis identified significant associations 
between lupus psychosis and anti-ribosomal P antibodies, although following 
adjustment for demographic variables, the 95% CIs around HRs were wide and 
included the null value, precluding a definitive conclusion regarding association of 
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this autoantibody with psychosis. This is consistent with an earlier report on NP 
events in the SLICC inception cohort (32). 
 
The potential role of corticosteroids must also be considered. In the current study, 
exposure to corticosteroids prior to lupus psychosis occurred in less than half of the 
initial events. As per the ACR case definition for psychosis (14), the concurrent use 
of corticosteroids at the onset of psychosis was identified as an “association” rather 
than a firm “exclusion”, indicating uncertainty about the role of corticosteroids in 
individual cases and to allow flexibility for determining attribution. Although NP 
symptoms have been reported with all types and doses of corticosteroids (33), 
including psychosis following intra-articular steroid injections (34, 35), in general the 
dose of corticosteroids is the most important risk factor. In the Boston Collaborative 
Drug Surveillance Program, the frequency of psychiatric symptoms of any type was 
18.6% in patients receiving >80 mg/day of prednisone, 4.6% in patients receiving 41-
80 mg/day and 1.3% in those receiving <40 mg/day. In the current study, exposure to 
corticosteroids prior to lupus psychosis was in the lowest of these dose ranges. 
 
Although the somatic toxicities of corticosteroids are well described, the literature on 
NP effects is considerably less. Their reported frequency varies widely from 2% to 
60% (36-38) and symptoms include affective, behavioural and cognitive 
manifestations (33). Moreover, the term “steroid psychosis” has been used to 
capture a heterogeneous group of NP effects, is not supported by validated 
diagnostic criteria and previous reports have included many patients who were not 
psychotic. The ACR case definition for psychosis (14), used in the current study, is 
based upon the Diagnostic and Statistical Manual of Mental Disorders, Fourth 
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Edition (DSM-IV) (39). In a previous study of 2,069 patients who received 
corticosteroids only 3 (0.14%) developed psychosis using DSM-IV criteria (40).  
 
One of the major advantages of our prospective study was the ability to document 
the short-term impact and long-term outcome of lupus psychosis from the 
perspective of both the physician and patient. In keeping with previous studies (6, 7) 
the physician assessments indicated resolution in the majority of cases with very few 
recurrences. Using a previously validated approach to measure the clinical outcome 
of NP events in SLE (18) we used summary and subscale scores of the SF-36 to 
assess the patient perspective. This is important because physician and patient 
assessment of outcome for other manifestations of SLE (41) and some NP events 
(42) may be discrepant. Although the greatest impact was on MCS scores it was 
apparent that all subscales of the SF-36 were negatively impacted in patients with 
lupus psychosis. However, following treatment and in keeping with physician 
assessment of outcome, the patient generated SF-36 scores showed a remarkable 
reversal when averaged over time.  
 
 
There are some limitations to the current study. First, the small number of patients 
with lupus psychosis limited our ability to precisely estimate potential associations 
with clinical or laboratory variables of interest. However, most of the previous studies 
have had an even smaller sample size and the SLICC cohort is the largest inception 
cohort of SLE patients. Second, specialized investigations such as advanced 
neuroimaging or cytokine profiling of CSF were not routinely performed but left to the 
discretion of individual investigators which reflects what is done in clinical practice, a 
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key component of our overall SLICC protocol. Third, the observational cohort study 
design precludes determination of optimal therapeutic regimes for lupus psychosis 
but rather reflects current standard of care.  Despite these limitations, the study 
provides encouraging data on the outcome of this rare but potentially devastating 
manifestation of NPSLE.  
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Legends for Figures 
Figure 1: The relationship between the time of onset of lupus psychosis and 
diagnosis of SLE. 
 
Figure 2: Physician determined outcome of lupus psychosis.  A: Survival curves for 
resolution. B: The highest and lowest Likert scale scores over the duration of follow-
up are shifted to the right indicating improvement. 
 
Figure 3: Association of SF-36 summary and subscale scores with lupus psychosis. 
A: mean (SD) physical component summary (PCS) and mental component summary 
(MCS) scores in 4 patient groups. Group 1 (n=29): visits in patients with onset of 
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lupus psychosis since last assessment or with an ongoing psychotic event; Group 2 
(n=3379): visits in patients with onset of other NP events since last assessment or 
ongoing other NP event(s), including non-SLE psychosis; Group 3 (n=2180): visits in 
patients with no NP events since last assessment and no ongoing NP event(s) but 
with a history of previous NP event(s); Group 4 (n=5893): visits in patients who never 
had NP event(s). The number of assessments contributing to each bar are 
aggregated for patients over time. 
B: comparison of individual subscale scores in the same 4 patient groups. The SF-
36 subscales are VT = Vitality, SF = Social function, RE = Role emotion, MH = 
Mental health, PF = Physical function, RP = Role physical, BP = Bodily pain, GH= 
General health. 
 
Figure 4: The long term change in SF-36 summary and subscale scores following 
resolution of lupus psychosis. 
A: mean (SD) physical component summary (PCS) and mental component summary 
(MCS) scores in 2 patient groups.  Psychosis group (n=29): visits in patients with 
onset of lupus psychosis since last assessment up to its resolution. Resolved group 
(n=112): visits in patients with resolution of lupus psychosis up to their last follow-up 
or recurrence of psychosis. If the psychotic event had both onset and resolution in 
the same interval prior to assessment, SF-36 scores at that assessment were 
included only in the psychosis group .The number of assessments contributing to 
each bar are aggregated for patients over time. 
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B: comparison of individual subscale scores in the same 2 patient groups. The SF-
36 subscales are VT = Vitality, SF = Social function, RE = Role emotion, MH = 
Mental health, PF = Physical function, RP = Role physical, BP = Bodily pain, GH= 
General health. 
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Table 1: Demographics, clinical features, medications, autoantibodies at enrolment. 
                     Number of Patients 1826 
Sex (%) Female 1622 (88.8) 
 Male 204 (11.2) 
Age (years) (mean ± SD)  35.1 ± 13.3 
Race/Ethnicity (%) Caucasian 891 (48.8) 
 African  306 (16.8) 
 Hispanic 282 (15.4) 
 Asian 275 (15.1) 
 Other 72 (3.9) 
Single/Married/Other (%)  818 (44.9)/766 (42.0)/238 (13.1) 
Post-secondary education (%)  1064 (61.9) 
Disease duration (months) (mean ± SD)  5.6 ± 4.2 
Number of ACR criteria (mean ± SD)  4.9 ± 1.1 
ACR manifestations (%) Malar rash 660 (36.1) 
 Discoid rash 227 (12.4) 
 Photosensitivity 652 (35.7) 
 Oral/nasal ulcers 677 (37.1) 
 Serositis 502 (27.5) 
 Arthritis 1368 (74.9) 
 Renal disorder 510 (27.9) 
 Neurological disorder 88 (4.8) 
 Hematologic disorder 1129 (61.8) 
 Immunologic disorder 1392 (76.2) 
 Antinuclear antibody 1731 (94.8) 
SLEDAI-2K score (mean ± SD)  5.3 ± 5.4 
*SLICC/ACR damage index score 
 (mean ± SD) 
  
0.32 ± 0.74 
Medications (%) Corticosteroids 1284 (70.3) 
 Antimalarials 1231 (67.4) 
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 Immunosuppressants 732 (40.1) 
 ASA 261 (14.3) 
 Antidepressants 183 (10.0) 
 Warfarin 99 (5.4) 
 Anticonvulsants 80 (4.4) 
 Antipsychotics 12 (0.7) 
Autoantibody positivity N (%) Lupus anticoagulant 241/1174 (20.5) 
 Anti-cardiolipin 138/1142 (12.1) 
 Anti-Beta2 
glycoprotein-I 
 
163/1142 (14.3) 
 Anti-ribosomal P 
Anti-NR2 
112/1136 (9.9) 
130/1064 (12.2) 
   
*SLICC/ACR damage index not available in 1057 patients at enrollment visit when disease duration < 6 
months 
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Table 2: Predictors of lupus psychosis by multivariate analysis. 
Predictor Factor level 
Hazard 
Ratio 
95% 
HR 
95% 
HR 
p 
(Wald) 
Other Concurrent 
NP events 
No concurrent NP events 1    
Any unresolved NP events attributed 
to SLE 
    3.59 1.16 11.14 0.027 
Any unresolved NP events not 
attributed to SLE  but no events 
attributable to SLE 
0.89 0.21 3.82 0.087 
Global (Wald) test    0.082 
      
Sex Female 1    
 Male 3.0 1.20 7.50 0.019 
      
Age at SLE 
diagnosis/10 
 0.69 0.48 0.99 0.044 
      
RACE Caucasian  1    
 African 4.59 1.79 11.76 0.002 
 Asian and Other 0.93 0.24 3.64 0.913 
 Hispanic 1.37 0.39 4.85 0.622 
 Global (Wald) test    0.005 
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